Airflows after inhalation of terbutaline sulphate aerosol from a 750-ml spacer for four weeks.
Terbutaline sulphate was administered to 40 adult asthmatic patients via an ordinary metered-dose inhaler (MDI) or one connected to a 750-ml spacer in an open, randomized, crossover study. Spirometry was obtained before the start of the study and again after four weeks of treatment with each inhaler. The patients recorded on a diary card the severity of their asthma symptoms and the peak expiratory flow rate (PEFR) in the morning before and after drug administration and in the evening. Preinhalation spirometric values were higher after four weeks with the 750-ml spacer than at the start of the study (P less than or equal to 0.05). Daily morning and evening PEFR values were higher after use of the 750-ml spacer than after use of the ordinary MDI (P less than 0.05). Daily symptom scores were generally low. A significantly better effect (P less than or equal to 0.05) with the 750-ml spacer was achieved only in daytime dyspnea. The investigators conclude that the attachment of a 750-ml spacer to an ordinary metered-dose inhaler can improve the efficacy of terbutaline sulphate in the long-term treatment of asthma.
N E
NE
Eriksson
K G
KG
Hidinger
L
L
Rosenhall
H
H
Hagstad
L
L
Löfgren
J
J
Perk
G
G
Stiksa
K
K
Ström
D000328:Adult; D000336:Aerosols; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D012123:Pulmonary Ventilation / Q000187:drug effects*; D011897:Random Allocation; D013147:Spirometry; D013726:Terbutaline / Q000008:administration & dosage*; D014797:Vital Capacity / Q000187:drug effects
D000336:Aerosols; D013726:Terbutaline